Shana Rose Coplowitz, MD Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 15 Laurel Ave Ste 100, Cornwall, NY 12518 Phone: 845-458-9000 Fax: 845-458-9001 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Across the European Union and the wider Europe, governments are engaged in cutting public expenditure and we are entering an unprecedented period of austerity. Thus, public support for research is now at risk in a manner not seen before and just at the time when Europe faces new challenges from the rising new economies, especially in Asia, and when threats to our quality of life from climate change, demographic change and energy, food and resource availability and sustainability are becoming evermore threatening and urgent.
PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.
Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.
› Verified 2 days ago